| Name | Title | Contact Details |
|---|
As the leading provider of targeted drug delivery (TDD) and infusion care, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected across our two divisions. ● A center of excellence in high-risk intrathecal compounding, AIS Healthcare Targeted Drug Delivery prepares and ships more than 140,000 patient-specific dispenses annually to all 50 states. We also offer comprehensive care services to support patients and empower providers, including in-home pump care and care coordination services. ● At Advanced Infusion Care, we provide high-quality intravenous (IV) and subcutaneous (SubQ) immunoglobulin therapies and in-home care to more than 1,500 patients across the country. Our nationally accredited home infusion team, including infusion nurse specialists and clinical pharmacists, partner closely with physicians to provide the best possible infusion care. AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC).
Cobb Psychotherapy is a group private practice providing mental health counseling services. Our therapists practice a range of interventions including evidence-based therapies traditional talk therapy.
ERT is a global company specializing in clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea`s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea`s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company`s pipeline through global partnering and commercialization efforts.